C.A. Uyl-de Groot

685 total citations
28 papers, 553 citations indexed

About

C.A. Uyl-de Groot is a scholar working on Economics and Econometrics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C.A. Uyl-de Groot has authored 28 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Economics and Econometrics, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C.A. Uyl-de Groot's work include Economic and Financial Impacts of Cancer (6 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). C.A. Uyl-de Groot is often cited by papers focused on Economic and Financial Impacts of Cancer (6 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). C.A. Uyl-de Groot collaborates with scholars based in Netherlands, Belgium and United States. C.A. Uyl-de Groot's co-authors include Frans Rutten, Peter C. Huijgens, LF Verdonck, Gouke J. Bonsel, Bob Löwenberg, Pieter Sonneveld, Michel van Agthoven, Edo Vellenga, Anton Hagenbeek and Dick J. Richel and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and European Journal of Cancer.

In The Last Decade

C.A. Uyl-de Groot

27 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.A. Uyl-de Groot Netherlands 12 258 118 116 115 78 28 553
Grant Lawless United States 13 328 1.3× 32 0.3× 85 0.7× 137 1.2× 59 0.8× 27 587
Pascal Chaı̈bi France 12 165 0.6× 147 1.2× 60 0.5× 39 0.3× 66 0.8× 33 528
Helen Farrugia Australia 15 264 1.0× 45 0.4× 51 0.4× 29 0.3× 57 0.7× 25 530
Cathy Allen Ireland 9 328 1.3× 539 4.6× 90 0.8× 64 0.6× 136 1.7× 17 1.0k
Jill Moormeier United States 11 230 0.9× 43 0.4× 128 1.1× 20 0.2× 45 0.6× 24 473
Anca Prica Canada 14 238 0.9× 141 1.2× 234 2.0× 24 0.2× 58 0.7× 130 609
Andrew Hantel United States 12 119 0.5× 123 1.0× 77 0.7× 103 0.9× 117 1.5× 60 499
Stephen S. Grubbs United States 10 354 1.4× 110 0.9× 40 0.3× 61 0.5× 74 0.9× 30 538
Yvan Coscas France 10 209 0.8× 55 0.5× 86 0.7× 30 0.3× 59 0.8× 37 461
Erin Zagadailov United States 12 100 0.4× 88 0.7× 76 0.7× 32 0.3× 24 0.3× 31 336

Countries citing papers authored by C.A. Uyl-de Groot

Since Specialization
Citations

This map shows the geographic impact of C.A. Uyl-de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.A. Uyl-de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.A. Uyl-de Groot more than expected).

Fields of papers citing papers by C.A. Uyl-de Groot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.A. Uyl-de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.A. Uyl-de Groot. The network helps show where C.A. Uyl-de Groot may publish in the future.

Co-authorship network of co-authors of C.A. Uyl-de Groot

This figure shows the co-authorship network connecting the top 25 collaborators of C.A. Uyl-de Groot. A scholar is included among the top collaborators of C.A. Uyl-de Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.A. Uyl-de Groot. C.A. Uyl-de Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mulder, Evalyn E.A.P., Dirk J. Grünhagen, Cornelis Verhoef, et al.. (2021). Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. ESMO Open. 6(6). 100303–100303. 12 indexed citations
2.
Groot, C.A. Uyl-de, et al.. (2019). PNS410 DATA FROM EXPANDED ACCESS PROGRAMS: TREATMENT FIRST, COLLECTION SECOND. AN OVERVIEW OF FDA AND EMA REGULATORY APPROVALS.. Value in Health. 22. S835–S835. 1 indexed citations
3.
Franken, M, Tim A. Kanters, J.L. Coenen, et al.. (2019). PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB. Value in Health. 22. S500–S500. 1 indexed citations
4.
Franken, M, Tim A. Kanters, J.L. Coenen, et al.. (2018). PCN85 - SAVING HEALTHCARE AND SOCIETAL COSTS BY CHANGING THE ROUTE OF ADMINISTRATION OF ONCOLOGY DRUGS. Value in Health. 21. S28–S28. 2 indexed citations
5.
Busschbach, Jan J.V., et al.. (2017). Developing a decision tool to identify patients with personality disorders in need of highly specialized care. BMC Psychiatry. 17(1). 317–317. 3 indexed citations
6.
Groot, Saskia de, Hedwig M. Blommestein, Ken Redekop, et al.. (2017). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PLoS ONE. 12(5). e0177364–e0177364. 8 indexed citations
7.
Groot, Saskia de, Stefan Sleijfer, Ken Redekop, et al.. (2016). Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. BMC Cancer. 16(1). 364–364. 9 indexed citations
8.
Bongers, Mathilda L., Dirk De Ruysscher, Cary Oberije, et al.. (2014). Calibration And Statistical Modeling To Inform A Micro-Simulation Model For Early HTA. Value in Health. 17(7). A561–A561.
9.
Tran, Linh M., et al.. (2014). 'DE NOVO' Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer. Value in Health. 17(7). A641–A641. 2 indexed citations
10.
Bongers, Mathilda L., Veerle M.H. Coupé, Dirk De Ruysscher, et al.. (2013). Pet-Based Radiotherapy Treatment Planning Is Highly Cost-Effective Compared to CT-Based Planning: A Model-Based Evaluation. Value in Health. 16(7). A414–A414. 1 indexed citations
11.
Linden, Naomi van der, et al.. (2013). Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results. European Archives of Oto-Rhino-Laryngology. 271(6). 1673–8. 8 indexed citations
12.
Franken, M, Siok Swan Tan, Ken Redekop, et al.. (2012). Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics. 38(1). 41–47. 41 indexed citations
13.
Blommestein, Hedwig M., S. Verelst, Peter C. Huijgens, et al.. (2012). Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of Hematology. 91(12). 1945–1952. 46 indexed citations
14.
15.
Tan, Siok Swan, C.A. Uyl-de Groot, Peter C. Huijgens, & Willem E. Fibbe. (2007). Stem cell transplantation in Europe: Trends and prospects. European Journal of Cancer. 43(16). 2359–2365. 12 indexed citations
16.
Groot, C.A. Uyl-de, et al.. (1999). Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995. Journal of Hematotherapy & Stem Cell Research. 8(6). 619–625. 4 indexed citations
17.
Vellenga, Edo, C.A. Uyl-de Groot, Ronald de Wit, et al.. (1996). Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.. Journal of Clinical Oncology. 14(2). 619–627. 69 indexed citations
18.
Groot, C.A. Uyl-de, et al.. (1996). An economic model to assess the savings from a clinical application of haematopoietic growth factors. European Journal of Cancer. 32(1). 57–62. 17 indexed citations
19.
Groot, C.A. Uyl-de, Frans Rutten, & Gouke J. Bonsel. (1994). Measurement and valuation of quality of life in economic appraisal of cancer treatment. European Journal of Cancer. 30(1). 111–117. 30 indexed citations
20.
Bonsel, Gouke J., Frans Rutten, & C.A. Uyl-de Groot. (1993). Economic evaluation alongside cancer trials: Methodological and practical aspects. European Journal of Cancer. 29. S10–S14. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grant Lawless Breakdown of academic impact, for papers by Pascal Chaı̈bi Breakdown of academic impact, for papers by Helen Farrugia Breakdown of academic impact, for papers by Cathy Allen Breakdown of academic impact, for papers by Jill Moormeier Breakdown of academic impact, for papers by Anca Prica Breakdown of academic impact, for papers by Andrew Hantel Breakdown of academic impact, for papers by Stephen S. Grubbs Breakdown of academic impact, for papers by Yvan Coscas Breakdown of academic impact, for papers by Erin Zagadailov
Rankless by CCL
2026